Free Trial

Silo Pharma (SILO) 10K Form and Latest SEC Filings 2026

Silo Pharma logo
$0.45 -0.01 (-2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$0.46 +0.01 (+1.55%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Silo Pharma SEC Filings & Recent Activity

Silo Pharma (NASDAQ:SILO) has submitted 162+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 424B3 submitted on April 16, 2026.

10-K
Silo Pharma Files Annual Report on Mar. 27, 2026

The 10-K contains Silo Pharma's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Silo Pharma SEC Filing History

Browse Silo Pharma's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/16/2026 3:15 PM
Silo Pharma (1514183) Filer
Form 424B3
04/15/2026 11:15 PM
Silo Pharma (1514183) Filer
Form EFFECT
04/14/2026 4:10 PM
Silo Pharma (1514183) Filer
Form 424B3
04/14/2026 3:38 PM
Silo Pharma (1514183) Filer
Form POS AM
04/13/2026 11:15 PM
Silo Pharma (1514183) Filer
Form EFFECT
04/10/2026 4:29 PM
Silo Pharma (1514183) Filer
Form POS AM
03/27/2026 3:40 PM
Silo Pharma (1514183) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/17/2026 9:24 AM
Anson Funds Management LP (1491072) Filed by
Silo Pharma (1514183) Subject
Form SCHEDULE 13G/A
02/13/2026 3:48 PM
INTRACOASTAL CAPITAL, LLC (1646799) Filed by
Silo Pharma (1514183) Subject
Form SCHEDULE 13G/A
02/13/2026 11:26 AM
SEG Opportunity Fund, LLC (2041952) Filed by
Silo Pharma (1514183) Subject
Form SCHEDULE 13G/A
12/29/2025 8:04 AM
Silo Pharma (1514183) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/16/2025 5:34 PM
Silo Pharma (1514183) Issuer
Weisblum Eric (1569077) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2025 11:15 PM
Silo Pharma (1514183) Filer
Form EFFECT
11/26/2025 3:15 PM
Silo Pharma (1514183) Filer
Form 424B3
11/21/2025 5:35 PM
Silo Pharma (1514183) Issuer
Weisblum Eric (1569077) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 3:00 PM
Silo Pharma (1514183) Issuer
Weisblum Eric (1569077) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 2:08 PM
Anson Funds Management LP (1491072) Filed by
Silo Pharma (1514183) Subject
Form SCHEDULE 13G
11/07/2025 4:30 PM
INTRACOASTAL CAPITAL, LLC (1646799) Filed by
Silo Pharma (1514183) Subject
Form SCHEDULE 13G/A
10/24/2025 3:39 PM
Silo Pharma (1514183) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2025 1:42 PM
SEG Opportunity Fund, LLC (2041952) Filed by
Silo Pharma (1514183) Subject
Form SCHEDULE 13G
10/01/2025 3:30 PM
Silo Pharma (1514183) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/01/2025 7:51 AM
Silo Pharma (1514183) Filer
Form 424B5
09/05/2025 4:05 PM
Silo Pharma (1514183) Filer
Form DEF 14A
09/05/2025 4:07 PM
Silo Pharma (1514183) Filer
Form ARS
09/05/2025 4:09 PM
Silo Pharma (1514183) Filer
Form DEFA14A
08/25/2025 3:25 PM
Silo Pharma (1514183) Filer
Form PRE 14A
07/10/2025 3:30 PM
Silo Pharma (1514183) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/03/2025 3:45 PM
Silo Pharma (1514183) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/28/2025 3:30 PM
Silo Pharma (1514183) Issuer
Weisblum Eric (1569077) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2025 6:00 PM
Pavell Jeff (1840601) Reporting
Silo Pharma (1514183) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2025 6:02 PM
Silo Pharma (1514183) Issuer
Weisblum Eric (1569077) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2025 6:02 PM
Ryweck Daniel E. (1652799) Reporting
Silo Pharma (1514183) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2025 6:03 PM
Munoz Kevin (1847763) Reporting
Silo Pharma (1514183) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2025 6:03 PM
Linsley Wayne (1809972) Reporting
Silo Pharma (1514183) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 4:19 PM
INTRACOASTAL CAPITAL, LLC (1646799) Filed by
Silo Pharma (1514183) Subject
Form SCHEDULE 13G
05/16/2025 8:08 AM
Silo Pharma (1514183) Filer
Form 424B4
05/15/2025 11:15 PM
Silo Pharma (1514183) Filer
Form EFFECT
(Data available from 1/1/2016 forward)

Silo Pharma SEC Filings - Frequently Asked Questions

Silo Pharma (SILO) has submitted 162+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Silo Pharma's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 424B3 submitted on April 16, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:SILO) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners